Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients

Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia

(2013) Julio Ramirez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tigecycline: an update

(2013) Gary E. Stein et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens

(2012) Zubair A. Qureshi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Carbapenem-Sparing Antibiotic Regimens for Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit

(2012) F. Sbrana et al.   CLINICAL INFECTIOUS DISEASES

Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy

(2012) M. Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

Excess Deaths Associated With Tigecycline After Approval Based on Noninferiority Trials

(2012) P. Prasad et al.   CLINICAL INFECTIOUS DISEASES

Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria

(2012) M. Akova et al.   CLINICAL MICROBIOLOGY AND INFECTION

Bloodstream infections caused by carbapenemase-producingKlebsiella pneumoniae: a clinical perspective

(2012) George L Daikos et al.   Expert Review of Anti-Infective Therapy

Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae

(2012) E.J. Ariza-Heredia et al.   Transplant Infectious Disease

Nosocomial Outbreak of VIM-1-Producing Klebsiella pneumoniae Isolates of Multilocus Sequence Type 15: Molecular Basis, Clinical Risk Factors, and Outcome

(2011) Isabel Sánchez-Romero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention

(2011) N. Gupta et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and safety of tigecycline: a systematic review and meta-analysis

(2011) Dafna Yahav et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia

(2010) Antonio T. Freire et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Superinfection during treatment of nosocomial infections with tigecycline

(2010) E. García-Cabrera et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation

(2010) D. E. Nix et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Diagnosis and Management of Complicated Intra‐abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

(2009) Joseph S. Solomkin et al.   CLINICAL INFECTIOUS DISEASES

Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint

(2009) Olaf Burkhardt et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis

(2009) E. Ediz Tutuncu et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Pharmacokinetic Considerations regarding Tigecycline for Multidrug-Resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii Urosepsis

(2009) B. A. Cunha   JOURNAL OF CLINICAL MICROBIOLOGY

Clinical and Microbiological Outcomes of Serious Infections with Multidrug-Resistant Gram-Negative Organisms Treated with Tigecycline

(2008) K. B. Anthony et al.   CLINICAL INFECTIOUS DISEASES

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae

(2008) K. Vasilev et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit

(2008) S. Swoboda et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY